Hepatitis C
203 results
1 - 100
Hepatitis C- MICROBIOLOGY
- CLINICAL
- SITES OF INFECTION
- TREATMENT
- General comments
- Treatment-naive
- Treatment failures
- HIV/HCV co-infection
- Cirrhotic patients
- Chronic kidney disease patients
- Regimens NOT recommended
- Follow-up
- Experimental and Future HCV Treatment Options
- Prevention
- OTHER INFORMATION
- Basis for recommendation
- References
- Hepatitis Due to Infections other than Hepatitis A, B, C, D, or E
- Ribavirin
- Daclatasvir
- Simeprevir
- Oteseconazole
- Hepatitis B (HBV) vaccines
- Viekira Pak
- Cobicistat
- Oritavancin
- Hepatitis A
- Interferon alpha (ABX)
- Glecaprevir + Pibrentasvir
- Nirmatrelvir/Ritonavir
- Sofosbuvir + Ledipasvir
- Technivie
- Tipranavir
- Gepotidacin
- Hepatitis A vaccine (HAV)
- Nevirapine
- Dalbavancin
- Sofosbuvir + velpatasvir
- Eravacycline
- Anidulafungin
- Bedaquiline
- Staging Liver Disease
- Isavuconazonium sulfate
- Quinine
- Tigecycline
- Elbasvir/Grazoprevir
- Nelfinavir
- Hepatitis D
- Bictegravir
- Sofosbuvir
- Fluconazole
- Delstrigo
- Doravirine
- Telithromycin
- Retroviral Syndrome, Acute
- Letermovir
- Hepatitis B
- Etravirine (ETR)
- Ticarcillin
- Piperacillin
- Metronidazole
- Lefamulin
- COVID-19 Convalescent Plasma
- Ticarcillin + Clavulanic Acid
- Myocarditis
- Caspofungin acetate
- Hep B-Hyperimmune globulin
- Flucloxacillin
- HIV, Occupational Exposure
- Intravenous immune globulin
- Myelitis